当前位置： SCI文献检索 > BREAST CANCER RESEARCH期刊下所有文献 > Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.

Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.

Abstract：

INTRODUCTION:Menopausal hormone therapies vary widely in their effects on breast cancer risk, and the mechanisms underlying these differences are unclear. The primary goals of this study were to characterize the mammary gland transcriptional profile of estrogen + progestin therapy in comparison with estrogen-alone or tibolone and investigate pathways of cell proliferation in a postmenopausal primate model. METHODS:Ovariectomized female cynomolgus macaque monkeys were randomized into the following groups: placebo (Con), oral conjugated equine estrogens (CEE), CEE with medroxyprogesterone acetate (MPA) (CEE + MPA), and tibolone given at a low or high dose (Lo or Hi Tib). All study treatment doses represented human clinical dose equivalents and were administered in the diet over a period of 2 years. RESULTS:Treatment with CEE + MPA had the greatest effect on global mRNA profiles and markers of mammary gland proliferation compared to CEE or tibolone treatment. Changes in the transcriptional patterns resulting from the addition of MPA to CEE were related to increased growth factors and decreased estrogen receptor (ER) signaling. Specific genes induced by CEE + MPA treatment included key members of prolactin receptor (PRLR)/signal transducer and activator of transcription 5 (STAT5), epidermal growth factor receptor (EGFR), and receptor activator of nuclear factor kappa B (RANK)/receptor activator of nuclear factor kappa B ligand (RANKL) pathways that were highly associated with breast tissue proliferation. In contrast, tibolone did not affect breast tissue proliferation but did elicit a mixed pattern of ER agonist activity. CONCLUSION:Our findings indicate that estrogen + progestin therapy results in a distinct molecular profile compared to estrogen-alone or tibolone therapy, including upregulation of key growth factor targets associated with mammary carcinogenesis in mouse models. These changes may contribute to the promotional effects of estrogen + progestin therapy on breast cancer risk.

journal_name

Breast Cancer Res

journal_title

Breast cancer research : BCR

authors

Wood CE,Branstetter D,Jacob AP,Cline JM,Register TC,Rohrbach K,Huang LY,Borgerink H,Dougall WC

doi

10.1186/bcr3456

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

R62

issue

eissn

1465-5411

issn

1465-542X

pii

bcr3456

journal_volume

pub_type

杂志文章

在线工具

Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.